BSE filing, NSE: DHAMPURE. Summary written from the filing by ALFA Finder's alert engine.
Dhampure Specialty Sugars Ltd: key numbers
- Share price
- ₹140.10
- Market cap
- ₹116.7 Cr
- Revenue (annual)
- ₹58.39 Cr
- Net profit (annual)
- ₹5.55 Cr
- P/E (TTM)
- 18.5×Sector 22.8×
- Promoter holding
- 60.27%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dhampure Specialty Sugars Ltd
All →Dhampure Specialty Sugars Board Meeting Date
Dhampure Speciality Sugars has given prior intimation of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated half-year results. The trading window stays closed from 1 September 2026 until 48 hours after results.
Dhampure Specialty Sugars Other Announcement
Dhampure Specialty Sugars Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Dhampure Specialty Sugars Other Announcement
Dhampure Speciality Sugars Limited filed its Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming dematerialization activity with its registrar.
Dhampure Specialty Sugars Management Change
Dhampure Speciality Sugars re-appointed Mr. Sorabh Gupta as Executive Director/MD/Chairperson for 36 months and Mrs. Praveen Singh as Non-Executive Non-Independent Director for 12 months.
Dhampure Specialty Sugars Annual General Meeting
Dhampure Specialty Sugars Limited held its 34th Annual General Meeting on September 15, 2026. Shareholders transacted agenda items including adoption of financial statements and director re-appointments.
Dhampure Specialty Sugars Annual Report
Dhampure Specialty Sugars Ltd has filed its Annual Report for the financial year 2025-26 as per SEBI regulations. The document is available on the company's website.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.